Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT03560011 Suspended - Clinical trials for Steroid-Dependent Nephrotic Syndrome

Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome

RITUXIVIG
Start date: April 3, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Idiopathic Nephrotic Syndrome (INS) is the first glomerulopathy in children and 60% of the patients develop Steroid-Dependant Nephrotic Syndrome (SDNS). Recently, rituximab (RTX), a humanized anti-CD20 antibody depleting B cells demonstrated the ability to increase relapse free survival and to decrease the number of relapse and the need of other immunosuppressive drugs. However, the remission rate after 2 years is only 30 to 40%. The aim of the study is to study the ability of intravenous Immunoglobulin to improve remission rate in SDNS when added associated with Rituximab compared to a treatment by Rituximab alone.

NCT ID: NCT03559946 Terminated - Clinical trials for Overactive Bladder Syndrome

Condensed Percutaneous Tibial Nerve Stimulation (PTNS) Protocol

Start date: June 8, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to understand how the frequency of PTNS sessions impacts their efficacy in the treatment of over active bladder syndrome.

NCT ID: NCT03558386 Completed - Clinical trials for Myelodysplastic Syndromes

Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes

Start date: July 23, 2018
Phase:
Study type: Observational

This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS).

NCT ID: NCT03557788 Completed - Clinical trials for Irritable Bowel Syndrome With Diarrhea

Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome

Start date: May 7, 2018
Phase: Phase 4
Study type: Interventional

Irritable Bowel Syndrome (IBS) carries a high prevalence worldwide and imposes substantial economic burden on patients, healthcare systems and society. In recent years, dysbiosis of the gut microbiota and bile acid (BA) malabsorption have been identified as putative pathophysiological mechanisms. Bile acid metabolism and gut microbiota are closely related. When patients with IBS-D were compared to healthy subjects, total levels of faecal BAs do not differ, but increased faecal primary BAs and reduced secondary BAs have been repeatedly observed in patients with IBS-D, suggesting abnormal BA deconjugation. Rifaximin, a non-absorbable antibiotic, has been shown in a recent meta-analysis to produce a therapeutic clinical gain compared to other treatment options for IBS, including placebo, paralleled by a high safety profile. It is also now known that changes in fecal microbiota have been observed in patients with IBS who have responded positively to Rifaximin. The relationship between microbiota changes, metabolomics changes after Rifaximin is unclear. There is emerging data to suggest duodenal dysbiosis as a putative pathophysiology, which in one study, clustered together with salivary microbiota than with fecal microbiota. However, the oral microbiome in patients with IBS has never been explored, which could possibly explain the downstream observations of duodenal and fecal dysbiosis. The investigators aim to assess the changes in metabolomic and microbiota profile after Rifaximin treatment, between responders and non-responders. The investigators will also explore the oral microbiome in IBS patients, and assess its relationship with fecal microbiome between responders and non-responders.

NCT ID: NCT03555188 Completed - Clinical trials for IBS - Irritable Bowel Syndrome

TReatment of Irritable Bowel Syndrome With Diarrhoea Using Titrated ONdansetron Trial

TRITON
Start date: March 29, 2018
Phase: Phase 3
Study type: Interventional

A placebo controlled study to determine the efficacy and mode of action of ondansetron in the treatment of irritable bowel syndrome with diarrhoea.

NCT ID: NCT03554031 Recruiting - Clinical trials for Prader-Willi Syndrome

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome

Start date: April 14, 2018
Phase: Phase 3
Study type: Interventional

To evaluate the effectiveness of rhGH (Recombinant human growth hormone) injection for improving motor development in patients with PWS.

NCT ID: NCT03553706 Completed - Clinical trials for Down Syndrome,Auxological Indexes, Auxological Parametars, Intrauterine Growth Restriction

Indicators of Growth, Nutritional Status and Comorbide Disorders of Newborns With Down Syndrome

DownSy
Start date: May 20, 2018
Phase:
Study type: Observational

Objective To access predictive values of the auxological parameters and indexes for risk of comorbid malformations in newborns with Down syndrome (DS) Study design In this cohort retrospective study, 141 newborns with proven trisomy 21 born at the Department of Gynecology and Obstetrics of the University of Split Hospital (1990 to 2015) were included. The data were obtained from the medical histories of mothers, infants and the delivery protocol. The objective was to access predictive values of the auxological parameters and indexes for risk of comorbid malformations in newborns with Down syndrome (DS) Conclusion Higher CI were found in hyportrophic (SGA) newborns with DS and indicated their intrauterine growth restriction with brain sparing and increased further risk of severe psychomotor retardation. The SGA newborns have lower parameters and indexes of nutritive status and significantly differed from eutrophic and hypertrophic newborns. These SGA newborns with DS have increased developmental risks and that requires further diagnostic attention.

NCT ID: NCT03553381 Completed - Metabolic Syndrome Clinical Trials

Oxidative Stress, Inflammation, and Lipoprotein in Metabolic Syndrome

Start date: December 30, 2010
Phase:
Study type: Observational

Obesity is associated with general low grade inflammation and, consequently, of oxidative stress that affects properties and functionality of lipoproteins. Metabolic syndrome exacerbate low grade inflammation. The intentional weight loss of at least 5% of the initial weight can modulate the pro-inflammatory state and reduce the oxidative stress related to the metabolic syndrome, thus diminishing the cardiovascular risk.

NCT ID: NCT03552848 Recruiting - Clinical trials for Multiple Organ Dysfunction Syndrome

Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

Multiple organ dysfunction syndrome (MODS) after surgical repaire for acute type A aortic dissection(ATAAD) is a life-threatening condition. In this study, patients who undergoing surgical repaire of ATAAD immdediately or presenting sever MODS after surgical repaire of acute type A aortic dissection will be treated with umbilical cord-derived mesenchymal stem cell.

NCT ID: NCT03551418 Terminated - Down Syndrome Clinical Trials

Learning by Repetitive Viewing of Peer Modeling Patient Education Videos by Adults With Down Syndrome

Start date: June 9, 2018
Phase: N/A
Study type: Interventional

The learning of appropriate hand washing technique through repetitive watching of a video depicting an adult with DS washing his hands will be studied.